ZAI LAB LIMITED Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ZAI LAB LIMITED stock issued during period, value, new issues for the quarter ending 2025-03-31 was -$28.00K.
- ZAI LAB LIMITED stock issued during period, value, new issues for the quarter ending 2021-06-30 was $818.00M.
- ZAI LAB LIMITED stock issued during period, value, new issues for the quarter ending 2021-03-31 was $62.25M, a 77.81% decline year-over-year.
- ZAI LAB LIMITED stock issued during period, value, new issues for the quarter ending 2020-06-30 was -$13.00K.
- ZAI LAB LIMITED stock issued during period, value, new issues for fiscal 2025 was -$28.00K, a 100.01% decline from fiscal 2024.
- ZAI LAB LIMITED stock issued during period, value, new issues for fiscal 2024 was $215.07M.
- ZAI LAB LIMITED stock issued during period, value, new issues for fiscal 2021 was $818.04M, a 191.58% increase from fiscal 2020.
- ZAI LAB LIMITED stock issued during period, value, new issues for fiscal 2020 was $280.55M, a 30.28% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | -$28.00K 10-K · filed 2026-02-26 | |
| 2025-03-31 | -$28.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $215.07M 10-K · filed 2026-02-26 | |
| 2021-12-31 | $818.04M 10-K · filed 2024-02-27 | |
| 2021-06-30 | $818.00M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $62.25M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $280.55M 10-K · filed 2023-03-01 | |
| 2020-06-30 | -$13.00K derived: 6-K 6 month − 10-Q 3 month · filed 2020-09-11 | $280.54M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $280.57M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | -$17.05K derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $215.35M 10-K · filed 2022-03-01 |
| 2019-09-30 | $1.05K derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | |
| 2018-12-31 | -$473.00 derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $140.35M 10-K · filed 2021-03-01 |
| 2017-12-31 | $157.66M 20-F · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |